AU2001268662A1 - Assembly of wild-type and chimeric influenza virus-like particles (VLPs) - Google Patents

Assembly of wild-type and chimeric influenza virus-like particles (VLPs)

Info

Publication number: AU2001268662A1
Authority: AU; Australia
Prior art keywords: vlps; influenza; protein; influenza virus; cells
Prior art date: 2000-06-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2001268662A

Other languages

English (en)

Inventor

Jose M. Galarza

Theresa E. Latham

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Wyeth Holdings LLC

Original Assignee

American Cyanamid Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-23

Filing date

2001-06-21

Publication date

2002-01-08

2001-06-21 Application filed by American Cyanamid Co filed Critical American Cyanamid Co

2002-01-08 Publication of AU2001268662A1 publication Critical patent/AU2001268662A1/en

2003-09-11 Assigned to WYETH HOLDINGS CORPORATION reassignment WYETH HOLDINGS CORPORATION Amend patent request/document other than specification (104) Assignors: AMERICAN CYANAMID COMPANY

Status Abandoned legal-status Critical Current

Links

206010022000 influenza Diseases 0.000 title claims abstract description 141
239000002245 particle Substances 0.000 title claims abstract description 52
241000712461 unidentified influenza virus Species 0.000 claims abstract description 64
101710172711 Structural protein Proteins 0.000 claims abstract description 18
101710154606 Hemagglutinin Proteins 0.000 claims description 145
101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 145
101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 145
101710176177 Protein A56 Proteins 0.000 claims description 145
239000000185 hemagglutinin Substances 0.000 claims description 136
108090000623 proteins and genes Proteins 0.000 claims description 124
102000004169 proteins and genes Human genes 0.000 claims description 81
108090001074 Nucleocapsid Proteins Proteins 0.000 claims description 66
108010006232 Neuraminidase Proteins 0.000 claims description 62
102000005348 Neuraminidase Human genes 0.000 claims description 61
108090000765 processed proteins & peptides Proteins 0.000 claims description 44
241000711975 Vesicular stomatitis virus Species 0.000 claims description 39
239000000203 mixture Substances 0.000 claims description 39
230000002163 immunogen Effects 0.000 claims description 25
238000000034 method Methods 0.000 claims description 23
108020004511 Recombinant DNA Proteins 0.000 claims description 22
108091006027 G proteins Proteins 0.000 claims description 19
102000030782 GTP binding Human genes 0.000 claims description 19
108091000058 GTP-Binding Proteins 0.000 claims description 19
108060003393 Granulin Proteins 0.000 claims description 19
102000004196 processed proteins & peptides Human genes 0.000 claims description 18
102000053602 DNA Human genes 0.000 claims description 17
108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
108010087302 Viral Structural Proteins Proteins 0.000 claims description 15
229920001184 polypeptide Polymers 0.000 claims description 15
239000003085 diluting agent Substances 0.000 claims description 13
241000251539 Vertebrata <Metazoa> Species 0.000 claims description 12
239000008194 pharmaceutical composition Substances 0.000 claims description 11
239000012228 culture supernatant Substances 0.000 claims description 10
239000002671 adjuvant Substances 0.000 claims description 8
244000000010 microbial pathogen Species 0.000 claims description 8
239000002773 nucleotide Substances 0.000 claims description 7
125000003729 nucleotide group Chemical group 0.000 claims description 7
108091026890 Coding region Proteins 0.000 claims description 6
108010061100 Nucleoproteins Proteins 0.000 claims description 5
102000011931 Nucleoproteins Human genes 0.000 claims description 5
102000004389 Ribonucleoproteins Human genes 0.000 claims description 5
108010081734 Ribonucleoproteins Proteins 0.000 claims description 5
230000001086 cytosolic effect Effects 0.000 claims description 5
230000001131 transforming effect Effects 0.000 claims description 5
238000012258 culturing Methods 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 2
210000004027 cell Anatomy 0.000 description 175
235000018102 proteins Nutrition 0.000 description 68
241000701447 unidentified baculovirus Species 0.000 description 49
239000013598 vector Substances 0.000 description 42
108020004414 DNA Proteins 0.000 description 39
238000012546 transfer Methods 0.000 description 31
238000001262 western blot Methods 0.000 description 30
208000015181 infectious disease Diseases 0.000 description 27
241000700605 Viruses Species 0.000 description 25
241000238631 Hexapoda Species 0.000 description 24
108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
241000699670 Mus sp. Species 0.000 description 20
239000013612 plasmid Substances 0.000 description 19
230000034303 cell budding Effects 0.000 description 18
239000006228 supernatant Substances 0.000 description 17
238000004458 analytical method Methods 0.000 description 15
230000015572 biosynthetic process Effects 0.000 description 13
230000003993 interaction Effects 0.000 description 13
238000001493 electron microscopy Methods 0.000 description 12
239000000499 gel Substances 0.000 description 12
230000003053 immunization Effects 0.000 description 12
238000013518 transcription Methods 0.000 description 12
230000035897 transcription Effects 0.000 description 12
150000001413 amino acids Chemical group 0.000 description 11
238000010367 cloning Methods 0.000 description 11
239000012634 fragment Substances 0.000 description 11
208000037797 influenza A Diseases 0.000 description 11
102000003886 Glycoproteins Human genes 0.000 description 10
108090000288 Glycoproteins Proteins 0.000 description 10
101150039660 HA gene Proteins 0.000 description 10
108060001084 Luciferase Proteins 0.000 description 10
101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 10
235000001014 amino acid Nutrition 0.000 description 10
239000012528 membrane Substances 0.000 description 10
239000013605 shuttle vector Substances 0.000 description 10
239000005089 Luciferase Substances 0.000 description 9
108010090054 Membrane Glycoproteins Proteins 0.000 description 9
102000012750 Membrane Glycoproteins Human genes 0.000 description 9
210000002845 virion Anatomy 0.000 description 9
230000003612 virological effect Effects 0.000 description 9
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 8
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 8
229940024606 amino acid Drugs 0.000 description 8
230000008569 process Effects 0.000 description 8
108700008625 Reporter Genes Proteins 0.000 description 7
239000000427 antigen Substances 0.000 description 7
108091007433 antigens Proteins 0.000 description 7
102000036639 antigens Human genes 0.000 description 7
210000000170 cell membrane Anatomy 0.000 description 7
238000005119 centrifugation Methods 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
238000003126 immunogold labeling Methods 0.000 description 7
238000010348 incorporation Methods 0.000 description 7
NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 7
238000000746 purification Methods 0.000 description 7
238000001890 transfection Methods 0.000 description 7
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 6
101710182846 Polyhedrin Proteins 0.000 description 6
229940098773 bovine serum albumin Drugs 0.000 description 6
230000029087 digestion Effects 0.000 description 6
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
230000000694 effects Effects 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
238000009472 formulation Methods 0.000 description 6
239000001963 growth medium Substances 0.000 description 6
230000028993 immune response Effects 0.000 description 6
229960004359 iodixanol Drugs 0.000 description 6
239000011159 matrix material Substances 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
238000004806 packaging method and process Methods 0.000 description 6
239000002953 phosphate buffered saline Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
101150082239 G gene Proteins 0.000 description 5
102000003960 Ligases Human genes 0.000 description 5
108090000364 Ligases Proteins 0.000 description 5
101150046652 M2 gene Proteins 0.000 description 5
101150080862 NA gene Proteins 0.000 description 5
239000013553 cell monolayer Substances 0.000 description 5
238000012217 deletion Methods 0.000 description 5
230000037430 deletion Effects 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
238000002649 immunization Methods 0.000 description 5
238000010166 immunofluorescence Methods 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
238000006386 neutralization reaction Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
238000013459 approach Methods 0.000 description 4
210000005220 cytoplasmic tail Anatomy 0.000 description 4
238000000635 electron micrograph Methods 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
239000010931 gold Substances 0.000 description 4
229910052737 gold Inorganic materials 0.000 description 4
230000035931 haemagglutination Effects 0.000 description 4
238000003119 immunoblot Methods 0.000 description 4
238000010185 immunofluorescence analysis Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 4
238000012163 sequencing technique Methods 0.000 description 4
238000010186 staining Methods 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
230000032258 transport Effects 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
241000283707 Capra Species 0.000 description 3
241000699800 Cricetinae Species 0.000 description 3
102000012410 DNA Ligases Human genes 0.000 description 3
108010061982 DNA Ligases Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
101710085938 Matrix protein Proteins 0.000 description 3
102000018697 Membrane Proteins Human genes 0.000 description 3
108010052285 Membrane Proteins Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
229930040373 Paraformaldehyde Natural products 0.000 description 3
108010067390 Viral Proteins Proteins 0.000 description 3
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 3
230000019552 anatomical structure morphogenesis Effects 0.000 description 3
230000000692 anti-sense effect Effects 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
241001493065 dsRNA viruses Species 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
108700010900 influenza virus proteins Proteins 0.000 description 3
210000003292 kidney cell Anatomy 0.000 description 3
239000003446 ligand Substances 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
239000002609 medium Substances 0.000 description 3
229920002866 paraformaldehyde Polymers 0.000 description 3
239000008188 pellet Substances 0.000 description 3
239000013641 positive control Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
238000003757 reverse transcription PCR Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
230000008685 targeting Effects 0.000 description 3
SICITCLFXRGKJW-IIZANFQQSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 SICITCLFXRGKJW-IIZANFQQSA-N 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
-1 529 (Corixa) Chemical class 0.000 description 2
KXEVYGKATAMXJJ-ACZMJKKPSA-N Ala-Glu-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KXEVYGKATAMXJJ-ACZMJKKPSA-N 0.000 description 2
208000037259 Amyloid Plaque Diseases 0.000 description 2
XEDQMTWEYFBOIK-ACZMJKKPSA-N Asp-Ala-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O XEDQMTWEYFBOIK-ACZMJKKPSA-N 0.000 description 2
KGHLGJAXYSVNJP-WHFBIAKZSA-N Asp-Ser-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O KGHLGJAXYSVNJP-WHFBIAKZSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
208000003322 Coinfection Diseases 0.000 description 2
241000759568 Corixa Species 0.000 description 2
108010017826 DNA Polymerase I Proteins 0.000 description 2
102000004594 DNA Polymerase I Human genes 0.000 description 2
241000233866 Fungi Species 0.000 description 2
101150066002 GFP gene Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
241001500351 Influenzavirus A Species 0.000 description 2
101710127721 Membrane protein Proteins 0.000 description 2
XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
241001494479 Pecora Species 0.000 description 2
MQWISMJKHOUEMW-ULQDDVLXSA-N Phe-Arg-His Chemical compound C([C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=CC=C1 MQWISMJKHOUEMW-ULQDDVLXSA-N 0.000 description 2
241000711798 Rabies lyssavirus Species 0.000 description 2
241000702670 Rotavirus Species 0.000 description 2
101710137500 T7 RNA polymerase Proteins 0.000 description 2
UNUZEBFXGWVAOP-DZKIICNBSA-N Tyr-Glu-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UNUZEBFXGWVAOP-DZKIICNBSA-N 0.000 description 2
LAYSXAOGWHKNED-XPUUQOCRSA-N Val-Gly-Ser Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LAYSXAOGWHKNED-XPUUQOCRSA-N 0.000 description 2
108020000999 Viral RNA Proteins 0.000 description 2
239000000910 agglutinin Substances 0.000 description 2
108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 2
239000013566 allergen Substances 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
244000309466 calf Species 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
238000010276 construction Methods 0.000 description 2
210000000172 cytosol Anatomy 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000009881 electrostatic interaction Effects 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 2
108010087823 glycyltyrosine Proteins 0.000 description 2
108010028295 histidylhistidine Proteins 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 2
238000003670 luciferase enzyme activity assay Methods 0.000 description 2
239000006166 lysate Substances 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 2
238000013508 migration Methods 0.000 description 2
230000005012 migration Effects 0.000 description 2
230000004001 molecular interaction Effects 0.000 description 2
239000003068 molecular probe Substances 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
239000000523 sample Substances 0.000 description 2
239000002356 single layer Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
239000003656 tris buffered saline Substances 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
241000606750 Actinobacillus Species 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000710929 Alphavirus Species 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
241000272478 Aquila Species 0.000 description 1
241000244186 Ascaris Species 0.000 description 1
NYGILGUOUOXGMJ-YUMQZZPRSA-N Asn-Lys-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O NYGILGUOUOXGMJ-YUMQZZPRSA-N 0.000 description 1
241000711404 Avian avulavirus 1 Species 0.000 description 1
241000335423 Blastomyces Species 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
241000589969 Borreliella burgdorferi Species 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
241000712083 Canine morbillivirus Species 0.000 description 1
241000282465 Canis Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
102000012406 Carcinoembryonic Antigen Human genes 0.000 description 1
108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
241001647372 Chlamydia pneumoniae Species 0.000 description 1
241001647378 Chlamydia psittaci Species 0.000 description 1
241000606153 Chlamydia trachomatis Species 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
241000193449 Clostridium tetani Species 0.000 description 1
241000711573 Coronaviridae Species 0.000 description 1
241000186227 Corynebacterium diphtheriae Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
241001337994 Cryptococcus <scale insect> Species 0.000 description 1
241000223935 Cryptosporidium Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
101150029707 ERBB2 gene Proteins 0.000 description 1
241000194032 Enterococcus faecalis Species 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000710803 Equine arteritis virus Species 0.000 description 1
241000711475 Feline infectious peritonitis virus Species 0.000 description 1
241000714165 Feline leukemia virus Species 0.000 description 1
241000701047 Gallid alphaherpesvirus 2 Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
241000224466 Giardia Species 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
YSDLIYZLOTZZNP-UWVGGRQHSA-N Gly-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN YSDLIYZLOTZZNP-UWVGGRQHSA-N 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
241000606768 Haemophilus influenzae Species 0.000 description 1
241000590002 Helicobacter pylori Species 0.000 description 1
241000711549 Hepacivirus C Species 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
241000709721 Hepatovirus A Species 0.000 description 1
241000606831 Histophilus somni Species 0.000 description 1
241000228402 Histoplasma Species 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
241000701806 Human papillomavirus Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241000702626 Infectious bursal disease virus Species 0.000 description 1
241000712431 Influenza A virus Species 0.000 description 1
206010022005 Influenza viral infections Diseases 0.000 description 1
102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000222732 Leishmania major Species 0.000 description 1
241000589929 Leptospira interrogans Species 0.000 description 1
241001293418 Mannheimia haemolytica Species 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000588655 Moraxella catarrhalis Species 0.000 description 1
108010008707 Mucin-1 Proteins 0.000 description 1
102100034256 Mucin-1 Human genes 0.000 description 1
241000711386 Mumps virus Species 0.000 description 1
241000186359 Mycobacterium Species 0.000 description 1
241000186364 Mycobacterium intracellulare Species 0.000 description 1
241000187479 Mycobacterium tuberculosis Species 0.000 description 1
241000204022 Mycoplasma gallisepticum Species 0.000 description 1
101150118742 NP gene Proteins 0.000 description 1
241000588652 Neisseria gonorrhoeae Species 0.000 description 1
241000588650 Neisseria meningitidis Species 0.000 description 1
108010065395 Neuropep-1 Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108700020497 Nucleopolyhedrovirus polyhedrin Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241000711504 Paramyxoviridae Species 0.000 description 1
241000606856 Pasteurella multocida Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010002747 Pfu DNA polymerase Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
241000235648 Pichia Species 0.000 description 1
241000233872 Pneumocystis carinii Species 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 1
108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
239000004365 Protease Substances 0.000 description 1
101710132653 Protein M2 Proteins 0.000 description 1
241000588769 Proteus <enterobacteria> Species 0.000 description 1
241000588770 Proteus mirabilis Species 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
241000711931 Rhabdoviridae Species 0.000 description 1
241000711897 Rinderpest morbillivirus Species 0.000 description 1
241000710799 Rubella virus Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241001138501 Salmonella enterica Species 0.000 description 1
241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
241000242678 Schistosoma Species 0.000 description 1
241000710961 Semliki Forest virus Species 0.000 description 1
241000607768 Shigella Species 0.000 description 1
241000713311 Simian immunodeficiency virus Species 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
241000256251 Spodoptera frugiperda Species 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
241000193985 Streptococcus agalactiae Species 0.000 description 1
241000193998 Streptococcus pneumoniae Species 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
108010046722 Thrombospondin 1 Proteins 0.000 description 1
102100036034 Thrombospondin-1 Human genes 0.000 description 1
241000223997 Toxoplasma gondii Species 0.000 description 1
241000224526 Trichomonas Species 0.000 description 1
241001489151 Trichuris Species 0.000 description 1
COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 description 1
241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
241000607626 Vibrio cholerae Species 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000003942 amyloidogenic effect Effects 0.000 description 1
206010002022 amyloidosis Diseases 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000011324 bead Substances 0.000 description 1
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
108091092328 cellular RNA Proteins 0.000 description 1
230000030570 cellular localization Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
210000003837 chick embryo Anatomy 0.000 description 1
229940038705 chlamydia trachomatis Drugs 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000002153 concerted effect Effects 0.000 description 1
108091036078 conserved sequence Proteins 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000000959 cryoprotective effect Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
244000309457 enveloped RNA virus Species 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
208000036912 glutaric acidemia IIb Diseases 0.000 description 1
102000035122 glycosylated proteins Human genes 0.000 description 1
108091005608 glycosylated proteins Proteins 0.000 description 1
VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
108010037850 glycylvaline Proteins 0.000 description 1
230000005484 gravity Effects 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
229940047650 haemophilus influenzae Drugs 0.000 description 1
229940037467 helicobacter pylori Drugs 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000003125 immunofluorescent labeling Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000002919 insect venom Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000010410 layer Substances 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
238000000464 low-speed centrifugation Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
230000034217 membrane fusion Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
235000013923 monosodium glutamate Nutrition 0.000 description 1
230000035772 mutation Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
244000309711 non-enveloped viruses Species 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
229940051027 pasteurella multocida Drugs 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000004033 plastic Substances 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000004850 protein–protein interaction Effects 0.000 description 1
230000010837 receptor-mediated endocytosis Effects 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229940073490 sodium glutamate Drugs 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000009987 spinning Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
229940031000 streptococcus pneumoniae Drugs 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
238000000856 sucrose gradient centrifugation Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000012134 supernatant fraction Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
239000012096 transfection reagent Substances 0.000 description 1
230000014616 translation Effects 0.000 description 1
230000010415 tropism Effects 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
231100000611 venom Toxicity 0.000 description 1
229940118696 vibrio cholerae Drugs 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16123—Virus like particles [VLP]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Microbiology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Animal Behavior & Ethology (AREA)
Oncology (AREA)
Pulmonology (AREA)
Public Health (AREA)
Communicable Diseases (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AU2001268662A 2000-06-23 2001-06-21 Assembly of wild-type and chimeric influenza virus-like particles (VLPs) Abandoned AU2001268662A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US21365600P	2000-06-23	2000-06-23
US60/213,656		2000-06-23
US28441101P	2001-04-17	2001-04-17
US60/284,411		2001-04-17
PCT/US2001/019890 WO2002000885A2 (fr)	2000-06-23	2001-06-21	Assemblage sauvage-chimerique de particules viraloïdes de la grippe (vlp)

Publications (1)

Publication Number	Publication Date
AU2001268662A1 true AU2001268662A1 (en)	2002-01-08

Family

ID=26908276

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AU2001268662A Abandoned AU2001268662A1 (en)	2000-06-23	2001-06-21	Assembly of wild-type and chimeric influenza virus-like particles (VLPs)
AU2007201727A Expired AU2007201727B2 (en)	2000-06-23	2007-04-18	Assembly of wild-type and chimeric influenza virus-like particles (VLPs)

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AU2007201727A Expired AU2007201727B2 (en)	2000-06-23	2007-04-18	Assembly of wild-type and chimeric influenza virus-like particles (VLPs)

Country Status (17)

Country	Link
US (2)	US7556940B2 (fr)
EP (1)	EP1294892B1 (fr)
JP (1)	JP5008244B2 (fr)
KR (1)	KR100877019B1 (fr)
CN (1)	CN1196788C (fr)
AT (1)	ATE376059T1 (fr)
AU (2)	AU2001268662A1 (fr)
BR (1)	BRPI0111830B8 (fr)
CA (1)	CA2410297C (fr)
CY (1)	CY1107835T1 (fr)
DE (1)	DE60130987T2 (fr)
DK (1)	DK1294892T3 (fr)
ES (1)	ES2295175T3 (fr)
IL (1)	IL153290A0 (fr)
MX (1)	MXPA02012254A (fr)
PT (1)	PT1294892E (fr)
WO (1)	WO2002000885A2 (fr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0250488A (ja) *	1988-08-11	1990-02-20	Nec Corp	超伝導配線
EP1294892B1 (fr) *	2000-06-23	2007-10-17	Wyeth Holdings Corporation	Assemblage sauvage-chimerique de particules virales de la grippe (vlp)
US9045727B2 (en) *	2002-05-17	2015-06-02	Emory University	Virus-like particles, methods of preparation, and immunogenic compositions
US20060088909A1 (en) *	2002-05-17	2006-04-27	Compans Richard W	Virus-like particles, methods of preparation, and immunogenic compositions
US20060121468A1 (en) *	2002-06-26	2006-06-08	Allnutt F C T	Viruses and virus-like particles for multiple antigen and target display
ES2217967B1 (es) *	2003-03-31	2006-01-01	Consejo Sup. Investig. Cientificas	Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv.
CN103074316B (zh)	2003-05-22	2015-10-21	美国弗劳恩霍夫股份有限公司	用于表达、传递及纯化目标多肽的重组载体分子
US8080255B2 (en)	2003-07-11	2011-12-20	Novavax Inc.	Functional influenza virus like particles (VLPs)
US8506967B2 (en)	2003-07-11	2013-08-13	Novavax, Inc.	Functional influenza virus like particles (VLPs)
US8551756B2 (en) *	2003-07-11	2013-10-08	Novavax, Inc.	Avian influenza chimeric VLPS
US8992939B2 (en)	2003-07-11	2015-03-31	Novavax, Inc.	Highly efficient influenza matrix (M1) proteins
AU2011218606B2 (en) *	2003-07-11	2012-01-12	Novavax, Inc	Functional influenza virus-like particles (VLPS)
US8592197B2 (en)	2003-07-11	2013-11-26	Novavax, Inc.	Functional influenza virus-like particles (VLPs)
ES2307345B1 (es) *	2004-01-21	2009-11-13	Consejo Sup. Investig. Cientificas	Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2307346B1 (es) *	2004-01-21	2009-11-13	Consejo Sup. Investig. Cientificas	Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
EP2811027A1 (fr) *	2004-05-21	2014-12-10	Novartis Vaccines and Diagnostics, Inc.	Vecteurs alphavirus pour vaccins contre le VRS et le PIV
KR20070114157A (ko) *	2005-02-16	2007-11-29	렌티겐 코포레이션	렌티바이러스 벡터 및 그의 용도
ES2310062B1 (es)	2005-07-15	2009-11-13	Bionostra, S.L.	Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
US8962278B2 (en)	2005-08-03	2015-02-24	Ibio Inc.	Compositions and methods for production of immunoglobulins
SI1937301T1 (sl) *	2005-10-18	2015-08-31	Novavax, Inc.	Funkcionalni influenčnemu virusu podobni delci (VLP)
CN101365479B (zh) *	2005-12-02	2013-06-26	纽约大学西奈山医学院	呈现非天然表面蛋白的嵌合病毒及其应用
EP1968632B1 (fr) *	2005-12-06	2012-04-11	Yeda Research And Development Co., Ltd.	Vaccin ameliore contre la grippe
MX2008009929A (es) *	2006-02-02	2008-10-01	Globeimmune Inc	Vacuna a base de levadura para inducir una respuesta inmune.
JP2009526526A (ja) *	2006-02-13	2009-07-23	フラウンホーファーユーエスエー，インコーポレイテッド	インフルエンザ抗原、ワクチン組成物、および関連する方法
WO2008048344A2 (fr) *	2006-02-13	2008-04-24	Fraunhofer Usa, Inc.	Antigènes de bacillus anthracis, compositions pour vaccins et procédés connexes
CN101395174B (zh) *	2006-02-13	2014-03-19	艾比欧公司	人类乳头瘤病毒（hpv）抗原、疫苗组合物和相关方法
EP3011969A1 (fr) *	2006-03-07	2016-04-27	Vaxinnate Corporation	Compositions incluant de l'hemagglutinine, procedes pour leur fabrication et leurs methodes d'utilisation
WO2007126788A2 (fr) *	2006-03-27	2007-11-08	Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Méthodes et compositions pour le traitement et la prévention d'une infection virale
US7682619B2 (en)	2006-04-06	2010-03-23	Cornell Research Foundation, Inc.	Canine influenza virus
US8778353B2 (en) *	2006-05-01	2014-07-15	Technovax, Inc.	Influenza virus-like particle (VLP) compositions
US9101578B2 (en) *	2006-05-01	2015-08-11	Technovax, Inc.	Polyvalent influenza virus-like particle (VLP) compositions
KR100702034B1 (ko) *	2006-05-12	2007-03-30	삼성전자주식회사	반도체 장치, 이 장치의 전원 노이즈 감소 방법 및 인쇄회로 기판
WO2007144886A2 (fr)	2006-06-15	2007-12-21	Ben-Gurion University Of The Negev Research And Development Authority	Particules de type viral destinées au traitement d'infections virales
WO2008036146A2 (fr)	2006-07-14	2008-03-27	Sanofi Pasteur Biologics Co.	Construction de vaccins antiviraux de recombinaison par insertion directe à médiation par transposon de déterminants immunologiques étrangers dans des protéines de virus vecteur
JP2009544322A (ja) *	2006-07-27	2009-12-17	リゴサイトファーマシューティカルズインコーポレイテッド	キメラウイルス様粒子
AU2007345768B2 (en) *	2006-07-27	2013-08-01	Ligocyte Pharmaceuticals, Inc.	Chimeric influenza virus-like particles
KR20090096414A (ko)	2006-09-29	2009-09-10	사노피 파스테르 바이오로직스 씨오	재조합 리노바이러스 벡터
US20100111996A1 (en) *	2006-11-15	2010-05-06	Denis Leclerc	Papaya Mosaic Virus-Based Vaccines for Influenza
ES2480491T3 (es) *	2006-12-06	2014-07-28	Novartis Ag	Vacunas incluyendo antígeno de cuatro cepas de virus de la gripe
WO2008100609A1 (fr) *	2007-02-16	2008-08-21	The Salk Institute For Biological Studies	Nouvelle antitoxine et plateforme vaccinale à base de vlp de nodavirus
EP2152301A4 (fr) *	2007-04-28	2010-07-28	Fraunhofer Usa Inc	Antigènes de trypanosome, compositions de vaccins et procédés associés
US8697088B2 (en)	2007-05-25	2014-04-15	Novavax, Inc.	VLPs derived from cells that do not express a viral matrix or core protein
WO2009009759A2 (fr)	2007-07-11	2009-01-15	Fraunhofer Usa, Inc.	Antigènes yersinia pestis, compositions de vaccins, et méthodes associées
CA2695399C (fr)	2007-08-02	2017-10-17	Biondvax Pharmaceuticals Ltd.	Vaccins contre la grippe a multiples epitopes multimeres
EP2190472A2 (fr) *	2007-08-20	2010-06-02	Fraunhofer USA, Inc.	Vaccins antigrippaux prophylactiques et thérapeutiques, antigènes, compositions et procédés
EA034733B1 (ru) *	2008-01-21	2020-03-13	Медикаго Инк.	Нуклеиновая кислота для увеличенной экспрессии гемагглютинина вируса гриппа в растении и ее применение
EP3115060A1 (fr)	2008-04-18	2017-01-11	VaxInnate Corporation	Mutants par délétion de la flagelline et procédés d'utilisation
US20110206727A1 (en) *	2008-07-30	2011-08-25	Denis Leclerc	Multivalent Vaccines Based on Papaya Mosaic Virus and Uses Thereof
WO2010037046A1 (fr)	2008-09-28	2010-04-01	Fraunhofer Usa, Inc.	Anticorps anti-neuraminidase humanisé et procédés d’utilisation de celui-ci
JP5642712B2 (ja)	2009-02-10	2014-12-17	ノバルティスアーゲー	少ない量のスクアレンを含むインフルエンザワクチン
JP2012525133A (ja) *	2009-05-01	2012-10-22	レッドバイオテック・アーゲー	多重遺伝子ベクターによってコードされる組換えウイルス様粒子
JP2012525830A (ja) *	2009-05-08	2012-10-25	グラクソスミスクラインバイオロジカルズソシエテアノニム	均質化を含む細胞培養からのウイルスの製造方法
PL222497B1 (pl) *	2009-06-26	2016-08-31	Inst Biochemii I Biofizyki Pan	Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania, kompozycja farmaceutyczna oraz zastosowanie wektorowej cząsteczki wirusopodobnej
EP2448596B1 (fr)	2009-07-02	2016-01-06	Massachusetts Institute of Technology	Compositions et procédés de diagnostic et/ou de traitement d'une infection grippale
EP2483307A1 (fr)	2009-09-29	2012-08-08	Fraunhofer USA, Inc.	Anticorps dirigés contre l'hémagglutinine du virus de la grippe, compositions, et procédés associés
US20110097358A1 (en) *	2009-10-12	2011-04-28	Techno Vax, Inc.	RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
JP5917402B2 (ja)	2009-11-03	2016-05-11	タケダヴァクシーンズ，インコーポレイテッド	キメラＲＳＶ−Ｆポリペプチド、およびレンチウイルスＧａｇまたはアルファレトロウイルスＧａｇに基づくＶＬＰ
JP6073031B2 (ja) *	2009-12-28	2017-02-01	タケダヴァクシーンズ，インコーポレイテッド	インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法
WO2011090731A1 (fr) *	2009-12-28	2011-07-28	Martek Biosciences Corporation	Production de polypeptides hétérologues dans micro-algues, corps extracellulaires de micro-algues, compositions et leurs procédés de fabrication et leurs utilisations
WO2011102900A1 (fr)	2010-02-18	2011-08-25	Technovax, Inc.	Vaccins universels contre la grippe à pseudo-particules virales (vlp)
CN102370976B (zh) *	2010-08-09	2014-06-11	中山大学	猪流感病毒和猪口蹄疫病毒的混合病毒样颗粒、制备方法和应用
CN102373183A (zh) *	2010-08-09	2012-03-14	中山大学	禽流感和新城疫混合病毒样颗粒、制备方法和应用
CN102373181B (zh) *	2010-08-09	2014-06-11	中山大学	猪流感病毒和猪蓝耳病病毒混合病毒样颗粒、制备方法和应用
CN102373182A (zh) *	2010-08-09	2012-03-14	中山大学	禽流感和传染性囊病混合病毒样颗粒、制备方法和应用
CN102373184A (zh) *	2010-08-09	2012-03-14	中山大学	禽流感和传染性支气管炎混合病毒样颗粒、制备方法和应用
EP2640405A4 (fr)	2010-09-21	2015-04-15	Massachusetts Inst Technology	Traitement et/ou caractérisation de la grippe ; polypeptides ha adaptés à l'homme
RU2663718C2 (ru)	2010-10-04	2018-08-08	Массачусетс Инститьют Оф Текнолоджи	Полипептиды гемагглютининов, а также связанные с ними реагенты и способы
US9821051B1 (en)	2010-10-28	2017-11-21	Seqirus UK Limited	Reducing hospitalization in elderly influenza vaccine recipients
AU2011360572B2 (en)	2011-02-22	2017-03-02	Biondvax Pharmaceuticals Ltd.	Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
BR112013032723A2 (pt)	2011-06-20	2017-01-31	Univ Pittsburgh Commonwealth Sys Higher Education	antígenos amplamente reativos computacionalmente otimizados para influenza h1n1
EP2739307B1 (fr) *	2011-08-01	2017-09-06	Emory University	Vlps contenant des ligands et leurs procédés associés
CN104185476A (zh) *	2011-09-20	2014-12-03	西奈山医学院	流感病毒疫苗及其应用
EP2827893B1 (fr)	2012-03-22	2017-11-29	Fraunhofer USA, Inc.	Particules pseudo-virales comprenant une protéine matricielle d'un virus enveloppé de plantes et leur utilisations
RU2639551C2 (ru)	2012-03-30	2017-12-21	Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн	Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вирусов гриппа h5n1 и h1n1
TWI434933B (zh) *	2012-04-17	2014-04-21	Nat Univ Tsing Hua	抗多型禽流感病毒之ｄｎａ疫苗及其組合物
US8932598B2 (en)	2012-08-28	2015-01-13	Vaxinnate Corporation	Fusion proteins and methods of use
RU2015124805A (ru)	2012-11-27	2017-01-13	Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн	Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вируса гриппа h1n1
AU2013362935B2 (en)	2012-12-18	2018-10-04	Icahn School Of Medicine At Mount Sinai	Influenza virus vaccines and uses thereof
US9908930B2 (en)	2013-03-14	2018-03-06	Icahn School Of Medicine At Mount Sinai	Antibodies against influenza virus hemagglutinin and uses thereof
US9228207B2 (en)	2013-09-06	2016-01-05	President And Fellows Of Harvard College	Switchable gRNAs comprising aptamers
US10080792B2 (en)	2013-09-23	2018-09-25	Engen Bio, Inc.	Influenza vaccine and therapy
CN104436157A (zh)	2013-09-23	2015-03-25	恩金生物有限公司	流感疫苗和治疗
CA2974699A1 (fr)	2015-01-23	2016-07-28	Icahn School Of Medicine At Mount Sinai	Regimes de vaccination contre le virus de la grippe
KR101729387B1 (ko)	2015-04-17	2017-04-21	경희대학교 산학협력단	곤충세포 발현시스템을 이용한 인플루엔자 백신 소재 ｍ1-ｍ2-ｎａ-ｈａ 바이러스 유사 입자의 제조방법
IL303336B2 (en)	2015-09-03	2025-08-01	Novavax Inc	Vaccine compositions having improved stability and immunogenicity
CN108367066B (zh) *	2015-09-10	2023-08-11	台湾地区“中央研究院”	包括类病毒颗粒及新型佐剂的禽流感疫苗组合物
CA3023143A1 (fr)	2016-06-15	2017-12-21	Icahn School Of Medicine At Mount Sinai	Hemagglutinines du virus de la grippe et utilisations de celles-ci
CN110325202B (zh) *	2016-10-31	2023-10-31	佐治亚州立大学研究基金会公司	乙型肝炎病毒pre-S蛋白的病毒样颗粒
KR20190123328A (ko)	2017-03-09	2019-10-31	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	암 백신
WO2018187706A2 (fr)	2017-04-07	2018-10-11	Icahn School Of Medicine At Mount Sinai	Anticorps anti-neuraminidase du virus influenza de type b et leurs utilisations
EP3658573A1 (fr)	2017-07-28	2020-06-03	President and Fellows of Harvard College	Procédés et compositions pour l'évolution d'éditeurs de bases à l'aide d'une évolution continue assistée par phage (pace)
CA3104297A1 (fr)	2018-06-21	2019-12-26	Icahn School Of Medicine At Mount Sinai	Polypeptides d'hemagglutinines du virus de la grippe en mosaique et leurs utilisations
JP7320601B2 (ja)	2018-09-11	2023-08-03	上▲海▼市公共▲衛▼生▲臨▼床中心	広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
MX2023012554A (es)	2018-12-12	2023-11-08	Cambridge Tech Llc	Vacuna universal contra la gripe.
WO2020154500A1 (fr)	2019-01-23	2020-07-30	The Broad Institute, Inc.	Protéines chargées supernégativement et utilisations associées
EP3956349A1 (fr)	2019-04-17	2022-02-23	The Broad Institute, Inc.	Éditeurs de base d'adénine présentant des effets hors cible réduits
CN114258398A (zh)	2019-06-13	2022-03-29	总医院公司	工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
IL300001A (en)	2020-07-24	2023-03-01	Massachusetts Gen Hospital	Enhanced virus-like particles and methods of use thereof for delivery to cells
CN116063409A (zh) *	2022-09-09	2023-05-05	中山大学·深圳	一种乙型流感Mosaic重组蛋白、重组质粒及其构建方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4009258A (en) *	1972-09-25	1977-02-22	The Mount Sinai School Of Medicine Of The City University Of New York	Influenza vaccine containing a recombinant, antigenically hybridized virus and method of using the same
US4666829A (en) *	1985-05-15	1987-05-19	University Of California	Polypeptide marker for Alzheimer's disease and its use for diagnosis
US6001634A (en) *	1989-08-28	1999-12-14	Palese; Peter	Recombinant negative strand RNA viruses
US5298244A (en) *	1990-10-25	1994-03-29	University Of Saskatchewan	Assembled viral particles and their use in a vaccine to rotaviral disease
US5830877A (en) *	1993-08-26	1998-11-03	The Regents Of The University Of California	Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
CA2323929C (fr)	1998-04-03	2004-03-09	University Of Iowa Research Foundation	Procedes et produits servant a stimuler le systeme immunitaire au moyen d'oligonucleotides et de cytokines immunotherapeutiques
DK1117435T3 (da)	1998-09-30	2008-03-17	Wyeth Corp	Muteret cholera-holotoxin som adjuvans
DE60035778T2 (de) *	1999-04-06	2008-04-30	Wisconsin Alumni Research Foundation, Madison	Rekombinante influenzaviren zur vakzinherstellung und gentherapie
EP1294892B1 (fr) *	2000-06-23	2007-10-17	Wyeth Holdings Corporation	Assemblage sauvage-chimerique de particules virales de la grippe (vlp)

2001
- 2001-06-21 EP EP01946643A patent/EP1294892B1/fr not_active Expired - Lifetime
- 2001-06-21 CA CA2410297A patent/CA2410297C/fr not_active Expired - Lifetime
- 2001-06-21 ES ES01946643T patent/ES2295175T3/es not_active Expired - Lifetime
- 2001-06-21 AT AT01946643T patent/ATE376059T1/de active
- 2001-06-21 WO PCT/US2001/019890 patent/WO2002000885A2/fr not_active Ceased
- 2001-06-21 IL IL15329001A patent/IL153290A0/xx unknown
- 2001-06-21 DE DE60130987T patent/DE60130987T2/de not_active Expired - Lifetime
- 2001-06-21 AU AU2001268662A patent/AU2001268662A1/en not_active Abandoned
- 2001-06-21 PT PT01946643T patent/PT1294892E/pt unknown
- 2001-06-21 BR BRPI0111830A patent/BRPI0111830B8/pt not_active IP Right Cessation
- 2001-06-21 DK DK01946643T patent/DK1294892T3/da active
- 2001-06-21 MX MXPA02012254A patent/MXPA02012254A/es active IP Right Grant
- 2001-06-21 CN CNB018116434A patent/CN1196788C/zh not_active Expired - Lifetime
- 2001-06-21 KR KR1020027017581A patent/KR100877019B1/ko not_active Expired - Lifetime
- 2001-06-21 JP JP2002506200A patent/JP5008244B2/ja not_active Expired - Lifetime
2005
- 2005-03-28 US US11/091,309 patent/US7556940B2/en not_active Expired - Lifetime
2007
- 2007-04-18 AU AU2007201727A patent/AU2007201727B2/en not_active Expired
- 2007-12-17 CY CY20071101598T patent/CY1107835T1/el unknown
2009
- 2009-06-02 US US12/476,649 patent/US8859231B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU2007201727A1 (en)	2007-05-10
DE60130987D1 (de)	2007-11-29
WO2002000885A3 (fr)	2002-08-08
DE60130987T2 (de)	2008-07-24
JP2004501647A (ja)	2004-01-22
WO2002000885A2 (fr)	2002-01-03
BR0111830B1 (pt)	2014-12-02
CY1107835T1 (el)	2013-06-19
ES2295175T3 (es)	2008-04-16
DK1294892T3 (da)	2008-01-28
KR20030013463A (ko)	2003-02-14
IL153290A0 (en)	2003-07-06
EP1294892A2 (fr)	2003-03-26
JP5008244B2 (ja)	2012-08-22
CA2410297A1 (fr)	2002-01-03
WO2002000885A9 (fr)	2002-05-10
US20090239261A1 (en)	2009-09-24
US7556940B2 (en)	2009-07-07
CN1437655A (zh)	2003-08-20
AU2007201727B2 (en)	2009-06-04
EP1294892B1 (fr)	2007-10-17
PT1294892E (pt)	2008-01-16
US20050186621A1 (en)	2005-08-25
BR0111830A (pt)	2003-03-25
CA2410297C (fr)	2011-03-15
US8859231B2 (en)	2014-10-14
KR100877019B1 (ko)	2009-01-07
CN1196788C (zh)	2005-04-13
BRPI0111830B8 (pt)	2021-05-25
MXPA02012254A (es)	2003-04-25
ATE376059T1 (de)	2007-11-15

Publication	Publication Date	Title
US8859231B2 (en)	2014-10-14	Assembly of wild-type and chimeric influenza virus-like particles (VLPs)
EP1644037B1 (fr)	2011-12-28	Particules pseudovirales fonctionnelles de la grippe (vlp)
EP1862550A1 (fr)	2007-12-05	Ensemble de particules de virus du type de la grippe chimérique et sauvage (VLP)
AU2011218606B2 (en)	2012-01-12	Functional influenza virus-like particles (VLPS)
HK1091118B (en)	2012-05-25	Functional influenza virus-like particles (vlps)

Legal Events

Date	Code	Title	Description
2007-05-17	MK5	Application lapsed section 142(2)(e) - patent request and compl. specification not accepted